Indivior PLC
LSE:INDV

Watchlist Manager
Indivior PLC Logo
Indivior PLC
LSE:INDV
Watchlist
Price: 1 238 GBX 1.56% Market Closed
Market Cap: 1.5B GBX

Operating Margin
Indivior PLC

25.6%
Current
26%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
25.6%
=
Operating Profit
529m
/
Revenue
2.1B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
UK
Indivior PLC
LSE:INDV
1.5B GBP
26%
US
Eli Lilly and Co
NYSE:LLY
993.4B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
508.5B USD
27%
CH
Roche Holding AG
SIX:ROG
256.1B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.1B GBP
24%
CH
Novartis AG
SIX:NOVN
206.4B CHF
33%
US
Merck & Co Inc
NYSE:MRK
243.7B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
142.5B USD
29%
No Stocks Found

Indivior PLC
Glance View

Indivior PLC, a pivotal player in the pharmaceutical landscape, traces its roots back to a dedicated focus on addiction treatment. With an origin steeped in addressing opioid dependency, the company carved out a significant niche by developing and marketing medication-assisted treatments. At the heart of Indivior's success is its flagship product, Suboxone, which combines buprenorphine and naloxone to manage opioid addiction. This formulation, integral in combating withdrawal symptoms and reducing the allure of opioids, positioned Indivior as an innovator in an era when the opioid crisis commanded urgent attention. The company's revenue model leverages the growing need for comprehensive drug dependence solutions, primarily driven by its robust portfolio of treatment options. By relentlessly advocating for effective healthcare policies and ensuring substantial product availability, Indivior maintains its competitive edge. The company's strategy is not just confined to novel drug development, but also focuses on expanding treatment access globally, aligning profitability with public health imperatives. This dual commitment to innovation and societal impact ensures that Indivior remains a significant force in the healthcare sector, adeptly navigating the complexities of addiction treatment while generating sustainable financial growth.

INDV Intrinsic Value
4 115.87 GBX
Undervaluation 70%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
25.6%
=
Operating Profit
529m
/
Revenue
2.1B
What is the Operating Margin of Indivior PLC?

Based on Indivior PLC's most recent financial statements, the company has Operating Margin of 25.6%.

Back to Top